Henrik Mei

Title: Henrik Mei: Innovator in Mass Cytometry

Introduction

Henrik Mei is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of mass cytometry, holding 2 patents that showcase his innovative approach to scientific challenges. His work focuses on the development of functionalized metal-labeled beads that enhance the accuracy and efficiency of mass cytometry assays.

Latest Patents

Henrik's latest patents include "Functionalized metal-labeled beads for mass cytometry" and "Platinum-labeled probes for mass cytometry." The first patent describes beads used as control, calibration, and quantification probes in mass cytometry assays. These beads are labeled with heavy metals such as osmium or ruthenium and feature surface functionalization that allows for the binding of affinity reagents, including metal-conjugated antibodies. The methods outlined in this patent facilitate the quantification of cell surface receptors and address channel crosstalk in mass cytometry assays. The second patent provides analyte-specific binding reagents conjugated with a platinum-containing moiety, such as cisplatin, along with methods, compositions, and kits for their production and use in analyte detection assays.

Career Highlights

Throughout his career, Henrik Mei has worked with esteemed institutions, including the Deutsches Rheuma-Forschungszentrum Berlin and Leland Stanford Junior University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Henrik has collaborated with notable colleagues, including Axel Ronald Schulz and Lisa Budzinski. These partnerships have further enriched his research and innovation in mass cytometry.

Conclusion

Henrik Mei's contributions to mass cytometry through his patents and collaborations highlight his role as an influential inventor in the scientific community. His work continues to pave the way for advancements in the field, enhancing the capabilities of mass cytometry assays.